What Pepticom Ltd. does

Pepticom Ltd. is a Jerusalem-based artificial intelligence company founded in 2015 that operates a computational platform for the discovery of novel therapeutic peptides. The core technology combines reinforcement learning, first-principles modeling, and generative AI to explore peptide chemical spaces of 10^80 possibilities using 600 natural and non-natural amino acids, with the stated design goal of producing peptide candidates optimized for stability, efficacy, and oral bioavailability within hours. The platform applies peptide-specific chemistries including cyclizations (N-to-C, Disulfide, Thioether, Lasso) and length adjustments of 5-13 amino acids, and integrates preclinical validation data to refine designs.

The business operates two complementary streams: paid discovery collaborations with multinational pharmaceutical and biotech companies, and an in-house pipeline led by an oral IL-17 inhibitor program for plaque psoriasis that the company describes as the world's first AI-designed therapeutic peptide for that indication. The lead asset is in lead optimization with a drug candidate announcement planned for 2025. Pricing is not publicly disclosed; revenue is generated through bespoke collaboration agreements rather than standardized product pricing.

Pepticom maintains research collaborations with Hebrew University of Jerusalem, Oxford University, the Fraunhofer Institute, and Hadassah University Medical Center, and holds a partnership with ADAMA in agricultural applications. In July 2025 it joined Johnson & Johnson's JLABS network as a virtual member across EMEA and Singapore. The company has published five peer-reviewed papers between 2015 and 2022 documenting its reinforcement learning methodology applied to specific therapeutic targets. Total disclosed funding is approximately $14.2 million across three rounds, most recently a $6.6 million Series A1 in January 2025 led by Japan Israel High Tech Ventures 2 LP. Headcount is 11-50 employees.

Name

Pepticom Ltd.

Legal name

Pepticom Ltd.

Website

https://pepticom.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Pepticom Ltd. is a Jerusalem-based AI company that uses reinforcement learning and generative AI to discover novel therapeutic peptides for pharmaceutical and agricultural partners, while advancing an in-house oral IL-17 inhibitor for plaque psoriasis.

Ownership category

akta.pro rank

Product category

AI-Driven Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH), Amino Acids & Peptides (BCAAs, Collagen Peptides, Bioactive Peptides, L-Theanine) (AFAJAKAG)

Keywords

• AI peptide discovery
• Drug discovery platform
• Peptide therapeutics
• Computational chemistry
• Generative AI drug design

Headquarters

HQ city

Jerusalem

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Drug Discovery Collaborations: Revenue generation through discovery collaboration deals with large multinational pharmaceutical and biotech companies. The company applies its AI platform to design and discover novel drug candidates for collaborative programs.
2. In-house Drug Development: Advancing proprietary drug pipeline through lead optimization, with plans to announce first drug candidate in 2025 for plaque psoriasis treatment (oral IL-17 inhibitors).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Pepticom operates an AI-driven peptide drug discovery platform that combines reinforcement learning, first-principles modeling, and generative AI to explore peptide chemical spaces of 10^80 possibilities using 600 natural and non-natural amino acids. The company designs and discovers novel therapeutic peptides for the pharmaceutical and agricultural markets through collaborative discovery agreements with multinational companies and through its own in-house drug development pipeline, including an oral IL-17 inhibitor program for plaque psoriasis.

Product overview

Pepticom offers a single unified AI-driven peptide drug discovery platform that combines reinforcement learning, first-principles modeling, and generative AI technologies. The platform enables rapid exploration of vast peptide chemical spaces (10^80 possibilities) and supports both in-house drug development programs and collaborative discovery projects with external partners. The company's lead in-house program focuses on developing oral IL-17 inhibitors for plaque psoriasis treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• AI-driven Peptide Drug Discovery Platform An AI-powered computational platform combining reinforcement learning, first-principles modeling, and generative AI to design and discover novel therapeutic peptides. Explores peptide spaces of 10^80 possibilities using 600 natural and non-natural amino acids to enable discovery of novel therapeutics for previously undruggable targets, unmet medical needs, and oral bioavailability improvement. Used for both in-house drug development and collaborative discovery projects with pharmaceutical and biotech partners.
• Collaborative Peptide Discovery Services Bespoke drug discovery collaboration services in which Pepticom applies its AI platform to design and discover novel peptide drug candidates for partner pharmaceutical and biotech companies. Customers engage through discovery collaboration deals with multinational companies.
• Oral IL-17 Inhibitor Program (Plaque Psoriasis) Pepticom's lead in-house drug development program focused on discovering novel oral IL-17 inhibitors for plaque psoriasis treatment, a major unmet medical need. Currently advancing what is believed to be the world's first AI-designed therapeutic peptide for psoriasis, with potential applications extending beyond psoriasis to additional indications.

Quantifiable outcome

• World's first AI-designed therapeutic peptide for psoriasis in lead optimization phase
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

Six partnerships are on record, tiered major and core.

• Johnson & Johnson Innovation JLABSmajorStrategic or Co-development Partner · 1 July 2025Pepticom is a virtual member company of Johnson & Johnson's global incubator network JLABS in EMEA and Singapore. JLABS is the largest global network of open innovation ecosystems enabling and empowering emerging companies with knowledge, experience, partnerships, and venture connections across pharmaceutical and medical technology sectors.
• Hebrew University of JerusalemcoreStrategic or Co-development PartnerAcademic collaboration with Hebrew University of Jerusalem. Co-founder Prof. Anwar Rayan is a researcher at the university. The university contributed to the development of peptide/protein structure prediction and drug discovery algorithms.
• Oxford UniversitycoreStrategic or Co-development PartnerAcademic collaboration partner. Dr. Shaul Lerner holds PhD and postdoc from the Weizmann Institute. The company has published research with Oxford-affiliated researchers.
• Fraunhofer InstitutecoreStrategic or Co-development PartnerResearch collaboration partner in peptide drug discovery and computational chemistry.
• Hadassah University Medical CentercoreStrategic or Co-development PartnerMedical research collaboration with Hadassah University Medical Center. Dr. Jonathan Cohen (SAB member) specializes in Cancer Research and Neuroscience at Hadassah.
• ADAMAcoreStrategic or Co-development PartnerCollaboration partner. ADAMA is a major multinational crop protection company, indicating cross-industry applications of Pepticom's technology.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Crinetics Pharmaceuticals: Clinical-stage peptide therapeutics company focused on oral peptide drug discovery and development, with overlapping focus on making peptides orally bioavailable—a core value proposition of Pepticom.

Direct peers

• Atomwise: AI-driven small molecule drug discovery company using structure-based deep learning, comparable as an early-stage AI drug discovery platform serving pharma collaborations.
• XtalPi: AI and quantum physics-driven drug discovery company offering predictive modeling and CRO services for pharma, comparable in combining computational platform with pharmaceutical partnerships.
• Insilico Medicine: AI-driven drug discovery company combining generative AI, reinforcement learning, and multi-modal biology to discover novel therapeutics, directly comparable to Pepticom's AI peptide platform approach.
• Iambic Therapeutics: AI-driven drug discovery company combining physics-based modeling and machine learning to discover novel therapeutics, with comparable scope in AI-first molecular design.
• Schrödinger, Inc. Computational chemistry and AI-driven molecular design platform used for drug discovery across pharma. Comparable as a software-plus-pipeline AI drug discovery company with both platform and proprietary assets.
• Cradle Bio: AI protein engineering company applying generative machine learning to design novel proteins and peptides, directly comparable to Pepticom's AI-driven peptide design capabilities.
• Recursion Pharmaceuticals: AI-driven biotechnology company combining high-throughput biology, machine learning, and generative chemistry to discover novel therapeutics at scale, comparable in mission and AI-first approach.
• Generate Biomedicines: Generative AI biology company creating novel protein therapeutics, with a similar focus on generative AI for biologic drug design including peptides and protein-based medicines.
• Isomorphic Labs: Alphabet-backed AI drug discovery company applying deep learning to pharmaceutical R&D, including protein structure prediction and small molecule design. Directly comparable as an AI-first drug discovery peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/pepticom
• YouTubeyoutube.com/@pepticom6510
• LinkedInlinkedin.com/company/pepticom-ltd.

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pepticom Ltd.